Puma Biotechnology stock (US7392761034): shares hover around 7 dollars ahead of next earnings update

Puma Biotechnology shares on Nasdaq traded just above the 7 dollar mark at the start of June 2026, leaving investors focused on recent trading dynamics and the timing of the company’s next quarterly earnings update in the United States biotech sector.

Puma Biotechnology shares on the Nasdaq in the United States started June 2026 trading a little above the 7 dollar level, with the stock changing hands at around USD 7.12 on 06/01/2026 according to Robinhood data as of 06/01/2026, keeping the name in focus among US small-cap biotech investors.

The stock, which is listed under the ticker PBYI on Nasdaq, has gained from the beginning of the year, rising from USD 5.95 to USD 7.17 by the close on 05/29/2026 according to MarketBeat as of 05/29/2026, amounting to a year-to-date increase of about 20.5 percent and underscoring how sentiment toward the company has improved in 2026.

In regular trading on 05/29/2026, MarketBeat reports that Puma Biotechnology closed at USD 7.17 with no change on the day, while extended-hours trading showed a marginal dip to USD 7.16 as of 06:34 PM Eastern, illustrating relatively stable price action heading into June.

Robinhood data for 06/01/2026 show that the shares reached an intraday high of USD 7.13 and a low of USD 6.84, ending the session around USD 7.12, which suggests intraday volatility but no decisive breakout from the recent trading range around the 7 dollar handle for this US biotech stock.

For investors in Germany tracking US biotechnology stocks, Puma Biotechnology is also available via German trading venues such as Tradegate, where the stock typically trades in euros based on the underlying Nasdaq listing, providing an additional access point outside regular US market hours.

The company is headquartered in California in the United States and remains listed on the Nasdaq, with no evidence of a completed take-private or delisting transaction; recent filings and trading activity confirm its status as an actively traded equity in the US biotech universe.

The latest company news from allowed sources, including Nasdaq and OTC Markets feeds, highlights routine corporate updates such as inducement awards granted under Nasdaq Listing Rule 5635(c)(4), as seen in a Puma Biotechnology announcement on OTC Markets dated 03/11/2026, which typically reflects equity-based compensation for new employees rather than a change in the fundamental outlook for the business.

The stock’s recent price consolidation around the 7 dollar level comes as investors look ahead to the timing of Puma Biotechnology’s next quarterly earnings report, with corporate event calendars from providers such as Benzinga showing the company’s conference calls and investor events on the Nasdaq timeline, even if the exact date for the upcoming quarter has yet to be confirmed on those schedules.

As of: 06/02/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Puma Biotechnology
• Sector/industry: Biotechnology / pharmaceutical products focused on oncology
• Headquarters/country: Los Angeles, United States
• Core markets: United States and selected international markets for oncology therapies
• Key revenue drivers: Sales of the breast cancer therapy neratinib (marketed as NERLYNX) and related licensing and collaboration revenue streams
• Home exchange/listing venue: Nasdaq (PBYI)
• Trading currency: USD

Puma Biotechnology: core business model

Puma Biotechnology concentrates on developing and commercializing targeted oncology therapies, with revenue primarily stemming from its neratinib-based breast cancer treatment franchise and associated commercialization and licensing agreements.

Latest quarterly results for Puma Biotechnology at a glance

As the calendar turns to June 2026, the most recent fully reported quarter for Puma Biotechnology remains its last published set of financial results, which detailed revenue trends from the commercialization of NERLYNX and related products as well as operating expenses tied to research, development, and commercialization activities, according to company investor materials and earnings releases filed with the US Securities and Exchange Commission around early 2026.

In that last reported quarter, management updated investors on prescription demand patterns for NERLYNX in the United States, international partnership performance and milestones, and the ongoing cost structure for clinical programs and post-marketing studies, setting a reference point that the market will likely revisit once Puma Biotechnology announces the date of its next quarterly earnings call on the Nasdaq corporate events calendar.

Conclusion

Puma Biotechnology’s stock is currently trading just above 7 dollars on the Nasdaq, following a roughly 20 percent gain since the start of 2026 and relatively calm day-to-day moves as of the beginning of June.

With the next quarterly earnings date yet to be formally set, investors are using the last reported results and ongoing neratinib commercialization trends as benchmarks, while monitoring corporate event calendars for confirmation of the upcoming report that could reframe expectations for the US biotech name.

This combination of steady trading, prior-year gains, and anticipation around the next earnings release keeps Puma Biotechnology on the radar of both US and European investors interested in oncology-focused biotechnology stocks.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.